Bionor Researchers to Present Data on Vacc-4x Phase IIB Trial at World Vaccine Congress, Washington, DC

[Washington, DC — 12 April 2012] Researchers from Bionor Pharma have been invited to present data at the World Vaccine Congress, on 13 April 2012. Chief Scientific Officer Maja Sommerfelt will present quality controlled data with more details on the findings issued in 1Q 2012 indicating a statistically significant drop in viral load for patients …

Read more

Results from Nasal Administration Study of HIV Vaccine Vacc-4x and Endocine Expected First Half of May

Oslo 10.04.2012 – Bionor Pharma ASA (OSE: BIONOR) today announces that the placebo controlled study of nasally administered HIV therapeutic vaccine Vacc-4x in combination with Eurocine Vaccines` Endocine has been finalized in Q1 as planned and previously communicated. 24 patients were included, and 23 completed the study. No serious adverse events have been reported. Analysis …

Read more

Related articles in 2012 regarding Vacc-4x

Here are a few links to articles released in 2012 regarding Bionor Pharma’s lead HIV therapeutic vaccine candidate Vacc-4x: Bloomberg : Bionor Rises Most in 15 Months on AIDS Drug Study: Oslo Mover Marketwire: With Final Review of Phase IIb Viral Load Data Completed……. Science on msnbc.com: New Vaccine Approach Gives Hope to Those Living with HIV